Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC).

Readers respond to the question of how prayer or intention has helped them make it through periods of great physical pain.

Weight-Loss Surgery Lowers Risk of Developing Complications of Liver Disease in Patients With Cirrhosis and Obesity Jan. 27, 2025 — A study shows that patients with obesity and fatty liver ...

This date is subsequently referred to as the “observational start date.” The primary analysis examined survival free of an event for these four outcomes: (1) colorectal cancer alone; (2) colorectal ...

ACLF clinical trials expected to initiate in 1Q253 clinical data readouts expected by year-end 2025 across the ACLF pipeline, including ...

ACLF clinical trials expected to initiate in 1Q253 clinical data readouts expected by year-end 2025 across the ACLF pipeline, including on-going UNVEIL-IT® Phase 2 trialData of on-going Phase 1b ...